Recludix Pharma Appoints Athena Countouriotis as Board Chairperson
Recludix Pharma has appointed Dr. Athena Countouriotis, a seasoned biotech leader and oncologist, as chairperson of its board of directors. With over two decades in the industry, including leadership roles at Turning Point Therapeutics, Adverum Biotechnologies, Halozyme Therapeutics, and others, she brings extensive experience in advancing drug development programs to approval. Countouriotis most recently led Turning Point through an IPO before its $4.1 billion acquisition by Bristol Myers Squibb in August 2022. She has also guided multiple companies through public offerings and acquisitions while contributing significantly to the clinical development of several oncology drugs at major pharmaceutical firms like Pfizer and Bristol-Myers Squibb. Recludix, a biotech firm focused on discovering inhibitors for challenging cancer targets using advanced drug discovery platforms, aims to leverage Countouriotis' expertise in accelerating its pipeline. Her appointment is expected to bolster the company’s strategic direction as it works toward developing novel therapies targeting proteins such as STAT6 and STAT3.
Topics: Biotech Industry Leadership Change